Results 181 to 190 of about 12,812,869 (370)
Pharmacognosy: The Study of Natural Drug Substances and Certain Allied Products
Robertson Pratt, Heber W. Youngken
openalex +2 more sources
STEROIDS AND RELATED NATURAL PRODUCTS XXIX. SODIUM BOROHYDRIDE – BORON TRIHALIDE REDUCTION OF 3-OXO-4-OXA-5α-CHOLESTANE [PDF]
George R. Pettit, William J. Evers
openalex +1 more source
Efgartigimod Combined With Steroid Treatment for HAM/TSP: A Case Report
ABSTRACT HTLV‐1‐associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a progressive neurological disorder with limited treatment options. We report a 54‐year‐old female with decade‐long, progressive HAM/TSP, previously refractory to rituximab, who experienced worsening spastic paraparesis and neurogenic bladder dysfunction.
Jiahui Zeng+5 more
wiley +1 more source
STEROIDS AND RELATED NATURAL PRODUCTS XXVI. SYNTHESIS OF 3β-ACETOXY-20-OXO-5β-PREGNA-14,16-DIENE [PDF]
George R. Pettit, David M. Piatak
openalex +1 more source
Long‐Term Evaluation of Givinostat in Duchenne Muscular Dystrophy, and Natural History Comparisons
ABSTRACT Objectives This ongoing, open‐label extension study is evaluating the long‐term safety, tolerability, and efficacy of givinostat, a Class I and II histone deacetylase inhibitor, in patients with Duchenne muscular dystrophy (DMD). Methods The recruited patients completed one of two prior clinical studies (one Phase 2 and one Phase 3 [EPIDYS ...
Craig M. McDonald+74 more
wiley +1 more source
Mass Spectrometry in Natural Product Chemistry [PDF]
John Harley-Mason
openalex +1 more source
Natural product discovery: past, present, and future
L. Katz, R. H. Baltz
semanticscholar +1 more source
Assessing a Mitochondrial Disease Treatment via a Novel Statistical Technique for Accelerometer Data
ABSTRACT Objective Therapeutic development for mitochondrial diseases, rare genetic disorders with pathogenic defects of oxidative phosphorylation, is hindered by unsatisfactory outcome measures. To address this problem, we provide the first clinical application of a novel, bias‐adjusted outcome measure of acceleration across a range of subjects ...
Ian W. McKeague+8 more
wiley +1 more source